Short Interest in HilleVax, Inc. (NASDAQ:HLVX) Expands By 7.4%

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 1,300,000 shares, an increase of 7.4% from the November 30th total of 1,210,000 shares. Based on an average trading volume of 195,800 shares, the short-interest ratio is presently 6.6 days. Currently, 5.9% of the company's shares are short sold.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HLVX. BML Capital Management LLC acquired a new position in HilleVax in the third quarter valued at about $35,000. Barclays PLC boosted its position in shares of HilleVax by 255.6% during the 3rd quarter. Barclays PLC now owns 42,033 shares of the company's stock worth $74,000 after purchasing an additional 30,213 shares during the period. GSA Capital Partners LLP acquired a new stake in HilleVax in the 3rd quarter valued at approximately $126,000. Jane Street Group LLC raised its position in HilleVax by 81.7% in the third quarter. Jane Street Group LLC now owns 79,039 shares of the company's stock valued at $139,000 after purchasing an additional 35,546 shares during the period. Finally, Zacks Investment Management lifted its stake in HilleVax by 411.9% during the third quarter. Zacks Investment Management now owns 92,803 shares of the company's stock worth $163,000 after purchasing an additional 74,673 shares in the last quarter. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

HilleVax Price Performance

Shares of HLVX traded up $0.09 during mid-day trading on Wednesday, reaching $2.07. The stock had a trading volume of 615,336 shares, compared to its average volume of 230,903. HilleVax has a 52-week low of $1.55 and a 52-week high of $20.22. The firm has a market cap of $103.11 million, a price-to-earnings ratio of -0.67 and a beta of 0.81. The business's fifty day moving average is $1.90 and its 200 day moving average is $3.09.

HilleVax (NASDAQ:HLVX - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.10). As a group, sell-side analysts anticipate that HilleVax will post -2.64 EPS for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.